 |
|
|
| |
Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world
populations of HCV patients over 70 years; data from the TRIO network
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Naoky Tsai1, Bruce Bacon2, Steven L. Flamm3, Kris Kowdley4, Eric Lawitz5, Scott Milligan6, Zobair Younossi7, Douglas T. Dieterich8
1Queens Medical Center, University of Hawaii, 2Saint Louis University School of Medicine, 3Northwestern University Feinberg School of Medicine, 4Liver Care Network, Swedish Medical Center, Seattle, WA, 5The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, 6Trio Health Analytics, 7Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 8Icahn School of Medicine at Mount Sinai
from Jules: take note of the patient dispositions in Table 3 where about 15% in the >70 group were deaths, lost-to-followup & discontinued, while the percent was lower for the <70 group.
|
| |
|
|
|
|
|
